Arcoxia

Etoricoxib

Symptomatic relief of OA, RA, & ankylosing spondylitis. Treatment of acute gouty arthritis, & acute pain eg, primary dysmenorrhea. Short-term treatment of moderate pain associated w/ dental surgery.

OA 30 or 60 mg once daily. RA & ankylosing spondylitis 60 mg once daily. Increase dose to 90 mg once daily in case of insufficient relief from symptoms, then titrate down to 60 mg once daily once stabilised. Acute gouty arthritis & primary dysmenorrhea 120 mg once daily. Max: 8 days. Post-op dental surgery pain 90 mg once daily. Max: 3 days. Patient w/ mild hepatic impairment (Child-Pugh score 5-6) Max: 60 mg once daily. Patient w/ moderate hepatic impairment (Child-Pugh score 7-9) Max: 60 mg every other day, or consider 30 mg once daily.

May be taken with or without food.

Hypersensitivity. Active peptic ulceration or GI bleeding. Patients experiencing bronchospasm, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria, or allergic-type reactions after taking ASA or NSAIDs including COX-2 inhibitors. Inflammatory bowel disease. CHF (NYHA II-IV). Hypertensive patients w/ BP persistently >140/90 mmHg. Established ischemic heart disease, peripheral arterial disease &/or cerebrovascular disease. Treatment of peri-operative pain in CABG surgery setting. Patients w/ severe hepatic impairment (serum albumin <25 g/L or Child-Pugh score ≥10); advanced renal disease (CrCl <30 mL/min). Pregnancy & lactation. Childn & adolescents <16 yr.

Increased risk of serious GI adverse events; serious CV thrombotic events, MI, & stroke. Not a substitute for ASA for prophylaxis of CV thromboembolic diseases. Renal papillary necrosis & other renal injury during long-term administration. Renal toxicity in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. Risk of fluid retention, oedema, & HTN. Control HTN before treatment. Monitor BP w/in 2 wk after treatment initiation & periodically thereafter. Reports of ALT &/or AST elevations. Discontinue treatment in case of signs of hepatic insufficiency or persistently abnormal LFTs. Caution when initiating treatment in patients w/ dehydration. Rehydrate patients prior to starting therapy. Reports of serious hypersensitivity reactions. Discontinue treatment at the 1st appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity. May mask fever & other signs of inflammation. Concomitant use w/ ASA (even at low doses); warfarin or other oral anticoagulants. Patients w/ rare hereditary problems of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption should not take this medicine. Patients experiencing dizziness, vertigo, or somnolence while on treatment should refrain from driving or operating machinery. Not recommended in women attempting to conceive.

Abdominal pain. Alveolar osteitis; oedema/fluid retention; dizziness, headache; palpitations, arrhythmia; HTN; bronchospasm; constipation, flatulence, gastritis, heartburn/acid reflux, diarrhea, dyspepsia/epigastric discomfort, nausea, vomiting, oesophagitis, oral ulcer; increased ALT & AST; ecchymosis; asthenia/fatigue, flu-like disease.

Increased prothrombin time & INR w/ warfarin. Reduced effect of diuretics, ACE inhibitors, & AIIA. Further renal function deterioration w/ ACE inhibitor or AIIA in patients w/ compromised renal function. Increased rate of GI ulceration or other complications w/ low-dose ASA. Increased nephrotoxic effect of cyclosporine or tacrolimus. Decreased renal excretion & increased plasma levels of lithium. Increased plasma conc & reduced renal clearance of MTX w/ 120 mg etoricoxib. Increased AUC of ethinyl estradiol, unconjugated estrone, equilin, & 17β-estradiol. Decreased plasma conc w/ rifampin.

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

M01AH05 - etoricoxib ; Belongs to the class of non-steroidal antiinflammatory and antirheumatic products, coxibs.

P₁S₁S₃